Abstract 43 Table 2
| Initial Audit GH 2012 | Re-audit GH 2017 | National Heart Failure Audit 2015–2016 | |
|---|---|---|---|
| LV imaging performed | 76.8% (43/56) | 91.8% (67/73) | 96% |
| ACEi/ARB with HFREF | 69.2% (18/26) | 85.7% (30/35) | 83% |
| Beta-blocker with HFREF | 65.4% (17/26) | 80.0% (28/35) | 87% |
| MRA with HFREF | 23.1% (6/26) | 62.9% (22/35) | 53% |
| Inpatient mortality | 14.3% (8/56) | 5.5% (4/73) | 6.6% |
| Mortality at 30 days after discharge | 6.3% (3/48) | 7.2% (5/69) (*) | 5.0% |
| Mortality at 6 months after discharge | 20.8% (10/48) | 17.4% (12/69) | n/a |
| Mortality at 12 months after discharge | 29.2% (14/48) | n/a | 30.5% |